SBMFF News and Press, Sino Biopharmaceutical Ltd

Sino Biopharm (1177.HK) Announces 2025 Annual Results HONG KONG, Mar 26, 2026 - (ACN Newswire) - Development Highlights - During the Year, the Group had 4 innovative products approved for marketing by the NMPA, namely, Saitanxin(R) (Culmerciclib Capsules), Hernexeos(R) (Zongerti...

2026-03-04 06:57:42 ET More on Sanofi, Sino Biopharmaceutical Limited Sanofi: CEO Leaves With Project Rejuvenation Unfinished, But Stock Undervalued Sanofi (SAN:CA) Q4 2025 Earnings Call Transcript Sanofi 2025 Q4 - Results - Earnings Call Presentation Sanofi ...

Sino Biopharm (1177.HK) Announces 2024 Annual Results HONG KONG, Mar 20, 2025 - (ACN Newswire) - Financial Highlights For the Year Ended 31 December RMB 2024 2023 Change RMB'Billion RMB'Billion (%) Revenue 28.87 26.20 +10.2% Gross profit margin (%) 81.5% 81.0% +0.5ppt ...